Netia Medical Technologies
Omaha
About Netia Medical Technologies
Netia will license the use of its single strand RNAi drug development platform to pharmaceutical companies; 6 patent filings undergird the technology. Netia's platform generates better drugs that are much less expensive. The cost to take a conventional drug to market averages $2.6B while a comparable drug based on Netia's platform costs less than half as much, and reduces the amount of time required to get to market by 3 years. Further, drugs based on the Netia platform can penetrate hundreds of therapeutic targets that are untouchable by conventional drugs.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $800.0K
- Funding stage: Seed
- Last round: Seed (Nov 2010)
- Website: netiamedtech.com
- Phone: [email protected]
Industries & Categories
Health Care, Medical, Therapeutics
Canonical: https://fsome.com/organization/netia-medical-technologies-764908 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.